Malignant Solid Tumour

Oncology
10
Pipeline Programs
9
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 8 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
2 programs
2
E7449 alonePhase 1/21 trial
EribulinPhase 1/21 trial
Active Trials
NCT01618136Completed41Est. Jul 2015
NCT01554371Completed44Est. Dec 2019
DS
Daiichi SankyoChina - Shanghai
1 program
1
TivantinibPhase 1/2Small Molecule1 trial
Active Trials
NCT01611857Completed49Est. Aug 2015
Novartis
NovartisBASEL, Switzerland
1 program
1
BEZ235Phase 11 trial
Active Trials
NCT01343498Completed33Est. Jan 2014
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BIBF 1120Phase 11 trial
Active Trials
NCT01951846Completed61
Ipsen
IpsenChina - Tianjin
1 program
1
BN80927Phase 11 trial
Active Trials
NCT01435096Completed56Est. Oct 2007
Bristol Myers Squibb
1 program
1
DasatinibPhase 1Small Molecule1 trial
Active Trials
NCT00388427Completed31Est. Feb 2013
M&
Merck & Co.RAHWAY, NJ
1 program
1
HydroxychloroquinePhase 11 trial
Active Trials
NCT01023737Completed72Est. Jan 2023
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
INNO-206Phase 11 trial
Active Trials
NCT01337505Completed24Est. Dec 2012
Vyriad
VyriadMN - Rochester
1 program
1
VSV-IFNβ-NISPhase 11 trial
Active Trials
NCT02923466CompletedEst. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daiichi SankyoTivantinib
EisaiEribulin
EisaiE7449 alone
VyriadVSV-IFNβ-NIS
NovartisBEZ235
ImmunityBioINNO-206
Merck & Co.Hydroxychloroquine
Bristol Myers SquibbDasatinib
IpsenBN80927
Boehringer IngelheimBIBF 1120

Clinical Trials (10)

Total enrollment: 411 patients across 10 trials

NCT01611857Daiichi SankyoTivantinib

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Start: Jul 2012Est. completion: Aug 201549 patients
Phase 1/2Completed
NCT01554371EisaiEribulin

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

Start: Mar 2012Est. completion: Dec 201944 patients
Phase 1/2Completed
NCT01618136EisaiE7449 alone

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Start: Jan 2012Est. completion: Jul 201541 patients
Phase 1/2Completed
NCT02923466VyriadVSV-IFNβ-NIS

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Start: Apr 2017Est. completion: Apr 2022
Phase 1Completed
NCT01343498NovartisBEZ235

Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

Start: Apr 2011Est. completion: Jan 201433 patients
Phase 1Completed
NCT01337505ImmunityBioINNO-206

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

Start: Apr 2011Est. completion: Dec 201224 patients
Phase 1Completed
NCT01023737Merck & Co.Hydroxychloroquine

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

Start: Nov 2009Est. completion: Jan 202372 patients
Phase 1Completed
NCT00388427Bristol Myers SquibbDasatinib

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

Start: Jun 2007Est. completion: Feb 201331 patients
Phase 1Completed
NCT01435096IpsenBN80927

BN80927 in Patients With Advanced Malignant Solid Tumors

Start: Nov 2004Est. completion: Oct 200756 patients
Phase 1Completed
NCT01951846Boehringer IngelheimBIBF 1120

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Start: Nov 200261 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)